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CRISPR RNA-guided FokI 
nucleases repair a PAH variant in a 
phenylketonuria model
Yi Pan1,*, Nan Shen2,*, Sabine Jung-Klawitter2, Christian Betzen3, Georg F. Hoffmann3, 
Jörg D. Hoheisel1 & Nenad Blau2,4
The CRISPR/Cas9 system is a recently developed genome editing technique. In this study, we used a 
modified CRISPR system, which employs the fusion of inactive Cas9 (dCas9) and the FokI endonuclease 
(FokI-dCas9) to correct the most common variant (allele frequency 21.4%) in the phenylalanine 
hydroxylase (PAH) gene - c.1222C>T (p.Arg408Trp) - as an approach toward curing phenylketonuria 
(PKU). PKU is the most common inherited diseases in amino acid metabolism. It leads to severe 
neurological and neuropsychological symptoms if untreated or late diagnosed. Correction of the 
disease-causing variants could rescue residual PAH activity and restore normal function. Co-expression 
of a single guide RNA plasmid, a FokI-dCas9-zsGreen1 plasmid, and the presence of a single-stranded 
oligodeoxynucleotide in PAH_c.1222C>T COS-7 cells – an in vitro model for PKU – corrected the PAH 
variant and restored PAH activity. Also in this system, the HDR enhancer RS-1 improved correction 
efficiency. This proof-of-concept indicates the potential of the FokI-dCas9 system for precision medicine, 
in particular for targeting PKU and other monogenic metabolic diseases.
Phenylketonuria (PKU, OMIM 261600) is the most frequent and important inherited metabolic disease, caused 
by deficiency of hepatic phenylalanine hydroxylase (PAH, EC 1.14.16.1). PAH converts phenylalanine (Phe) to 
tyrosine (Tyr). The cofactor tetrahydrobiopterin (BH4), iron and molecular oxygen are required for this process1. 
PAH deficiency results in the accumulation of Phe in the body including the brain. If untreated or diagnosed 
late, its high concentration leads to severe neurological and neuropsychological symptoms, including intellectual 
disability, seizures, ataxia, motor deficits and behavioral problems. Because of the severity of the disease, newborn 
screening for PKU has been instituted in many countries. Lifelong restriction of dietary Phe is the established 
treatment for preventing neuronal damage. However, poor compliance by PKU patients and the heavy economic 
burden challenge the dietary management. Although the restriction of dietary Phe improves cognitive perfor-
mance, other neuropsychological parameters such as choice reaction time, attention, and executive functions 
are impaired compared to healthy controls even in the best treated individuals. An additional supplement of 
tetrahydrobiopterin (BH4; sapropterin dihydrochloride) may be beneficial for some PKU patients with a mild 
pheotype2. However, the ideal approach for curing PKU would be to correct variants in the PAH gene directly 
through gene therapy. Since PKU is an autosomal recessive inherited disorder, only individuals with PAH variants 
located in both alleles develop symptoms. Even if only one allele is corrected, the residual PAH activity would be 
sufficiently increased, abolishing or reducing PKU symptoms. In patients with severe classic PKU, the c.1222C>T 
(p.Arg408Trp) single nucleotide variant is the most frequent one in PAH (allele frequency 21.4%) and p.[Arg-
408Trp];[Arg408Trp] the most common genotype (genotype frequency 10.2%)3. Thus, PAH_c.1222C>T was 
chosen as the target in this study.
The most promising genetic repair of variants is achievable through homologous recombination repair 
(homology directed repair; HDR) after the introduction of DNA double-stranded breaks (DSBs) close to the var-
iant. DSBs can be generated by different genome editing technologies, such as zinc-finger nucleases (ZFNs), tran-
scription activator-like effector nucleases (TALENs) and the recently developed technique of clustered regularly 
interspaced short palindromic repeats (CRISPR)4. The CRISPR/Cas9 system was first identified as a prokaryotic 
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defense mechanism against bacteriophages, and is currently being used for site-specific genome editing. It is com-
posed of a single-guide RNA (sgRNA) containing a 20 nt sequence that targets a specific genomic site and one Cas9 
nuclease that enables the cleavage of genomic DNA. The DSBs then stimulate the DNA repair pathway through 
non-homologous end joining (NHEJ) and HDR. Of these mechanisms, HDR can generate the desired sequence 
replacement at the DSBs through the usage of a donor DNA template, which corrects the specific variant within 
the genome5. Several studies have recently reported encouraging results using CRISPR/Cas9 for successful thera-
peutic concepts, such as Duchenne muscular dystrophy and retinitis pigmentosa in vitro and in vivo6–10. However, 
there are still two major challenges in the CRISPR/Cas9-mediated genome correction: frequent off-target effects 
and low HDR efficiency5,11,12. To overcome these problems, different strategies were adopted in this study. First, 
we chose the CRISPR RNA-guided FokI nuclease system (FokI-dCas9 system)13–15 instead of the CRISPR/Cas9 
system as the specific genome editing tool. The FokI-dCas9 system is composed of two distinct sgRNAs and 
FokI-dCas9 nuclease, which is a fusion of inactive Cas9 (dCas9) and the FokI endonuclease. The FokI-dCas9 sys-
tem differs from CRISPR/Cas9 in that the simultaneous binding of two distinct FokI-dCas9:sgRNAs is required. 
Moreover, we employed 3-(N-benzylsulfamoyl)-4-97 bromo-N-(4-bromophenyl)benzamide (RS-1), an HDR 
enhancer16,17, as a RAD51-stimulatory compound18. By this means, we successfully performed a genetic repair of 
the c.1222C>T PAH variant, which for the first time corrected the point variant and rescued both PAH protein 
expression and activity.
Results
Establishment of the PAH_c.1222C>T COS-7 cell line as an in vitro PKU model. The PAH_c.1222C>T 
variant was introduced into COS-7 cells by transfection with an appropriately modified vector DNA. Single clones 
were sub-cultured for at least 15 passages. Sanger sequencing analysis proved that the “T” point variant was 
appropriately located in PAH (Fig. 1a). Reverse transcription PCR (RT-PCR) confirmed that PAH_c.1222C>T 
was expressed in the transfected COS-7 cells at the RNA level at a similar level as the wild-type protein used in 
control; untransfected COS-7 cells exhibited no PAH RNA (Fig. 1b). Concurrently, Western blot analysis with an 
antibody against the wild-type protein (PAH_WT) revealed a basically complete loss of the PAH protein in the 
cells transfected with the mutated gene version (Fig. 1c).
The PAH_c.1222C>T variant was corrected using the FokI-dCas9 system. The FokI-dCas9 sys-
tem is different from the CRISPR/Cas9 system insofar as only binding of a FokI-dCas9 dimer can cleave DNA 
(Fig. 2a). After electroporation of COS-7 cells with expression vectors of the FokI-dCas9 gene and the sgRNA, 
flow cytometry analysis showed that approximately 18.4% of cells co-expressed them simultaneously (Fig. 2b). In 
presence of RS-1, PAH expression in PAH_c.1222C>T COS-7 cells treated with 0.5 or 1 nM of the single-stranded 
oligodeoxynucleotide (ssODN) that represents the replacement sequence was significantly higher than the PAH 
expression of PAH_c.1222C>T COS-7 cells that were not transfected with the vectors. A lower ssODN concen-
tration had no apparent effect on PAH expression (Fig. 2c). Furthermore, liquid chromatography-electrospray 
ionization tandem mass spectrometry was employed to evaluate the PAH activity after repair (Fig. 2d), confirm-
ing the results of the Western blot analysis. Sanger sequencing analysis was performed to confirm the correction 
in all groups. The 1 nM ssODN and 0.5 nM ssODN groups showed double-peaks at the corrected position regard-
less of RS-1 treatment, demonstrating the presence of both a “T” and a “C” at the PAH_c.1222C>T variant in 
Figure 1. PAH_c.1222C>T COS-7 cell line was established as a PKU in vitro model. (a) Sanger sequencing 
analysis of PAH_c.1222C>T COS-7 cells by IRES reverse primer showed “A” point mutation on the PAH gene. 
(b) RT-PCR confirmed PAH_c.1222C>T expression in established cell line. (c) Western blot showed that the 
expression of PAH in PAH_c.1222C>T cells was lower than in PAH_WT cells.
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the cell population (Supplementary Fig. 1a). To examine the correction rate, we amplified by PCR target DNA 
from the 1 nM ssODN with RS-1 treatment group and verified the sequence by TA-cloning. Sequence analysis of 
the DNA of 30 colonies showed that 8 of them (26.7%) contained the correct “C” (Fig. 2e). To assess the possible 
off-targeting introduced by FokI-dCas9-directed cleavage, two potential off-target sites were predicted by CasOT 
(Supplementary Table 1). Both potential sites were analyzed together with the PAH gene on-target site by Sanger 
sequencing. None of the analyzed regions showed evidence of off-target cleavage (data not shown).
Figure 2. Correction of the PAH_c.1222C>T variant in COS-7 cells. (a) Scheme of the process: one dimer 
of the FokI-dCas9 complex binds to two “half-sites” on the genome with a certain spacer length and generate 
DSBs. DSBs are then repaired by HDR. (b) Co-expression efficiency of the FokI-dCas9 and sgRNA plasmids in 
PAH_c.1222C>T COS-7 cells was analyzed by flow cytometry. (c) The PAH expression of each cell population 
was detected by Western blot. (d) The PAH activity of each group was measured by liquid chromatography-
electrospray ionization tandem mass spectrometry. (e) Correction of variant; one of 30 sequences are shown. 
T/A-cloning into E. coli and Sanger sequencing were performed on DNA isolated from individual COS-7 cells 
transfected with the FokI-dCas9 and sgRNA plasmids as well as 1 nM ssODN and treated with RS-1. Among all 
30 randomly picked colonies, representing the DNA of 30 COS-7 cells, 26.7% of the cells exhibited correction of 
the variant.
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Discussion
Although the restriction of dietary Phe and/or supplementation with BH4 can substantially alleviate clinical 
symptoms of PKU, patients do not manage to maintain dietary treatment for life. They suffer from impaired 
neuropsychological and partly from intellectual function and PKU women are at risk for the maternal PKU syn-
drome. The ideal approach to treating this disease would be a correction of the PAH variant. PKU gene therapy 
has been developed over the past two decades using an animal model. Researchers delivered the wild-type PAH 
gene to tissues with an adeno-associated virus (AAV) vector. However, the temporary recovery of PAH activity, 
risks associated with the AAV vector or a very low gene transfer rate in the past limited the development of this 
treatment option19,20. Ongoing research is focused on new genome editing technologies that can correct genomic 
variants. Therefore, in this study the FokI-dCas9 system was chosen to correct with high accuracy and efficiency 
the most common PAH variant in cells.
The CRISPR/Cas9 system stimulates DNA repair mechanisms such as NHEJ and HDR. NHEJ leads to ran-
dom deletion or insertion variants close to the DSB site, resulting in gene knock out, while HDR can generate a 
desired sequence replacement at the DSB by donating a DNA template, resulting in gene correction. Despite the 
tremendous potential of the original CRISPR/Cas9 system21, several challenges still limit its application to gene 
therapy. For example, the short 20 bp target sequence required in the sgRNA, of the commonly used SpCas9 
system may cause off-target effects elsewhere in the genome12. Moreover, NHEJ is the dominant mechanism for 
repairing DSBs after DNA cleavage in mammals, preventing gene correction by HDR. Thus, new strategies that 
avoid off-target effects and increase the HDR:NHEJ ratio are needed22.
The FokI-dCas9 system can greatly improve the specificity of genome editing in vitro and in vivo. In con-
trast to the CRISPR/Cas9 system, it requires dimerization of the FokI-dCas9-sgRNA complex, meaning that 
monomeric FokI-dCas9-sgRNA is unable to cut the DNA strand14. Three rules are used in designing a specific 
FokI-dCas9-sgRNA complex that retains high cleavage efficiency. First, the pair of sgRNAs should bind to sense 
and antisense strands. Second, two distinct FokI-dCas9-sgRNA-binding “half-sites” must be located close to 
the targeted genomic position, and third, the FokI-dCas9-sgRNA complex requires a particular orientation. 
Generally, having protospacer adjacent motif (PAM) sequences for the two distinct FokI-dCas9-sgRNA com-
plexes located on the outer boundaries of the target site (“PAM-out” orientation) is superior to having them 
connected directly to the spacer sequence (“PAM-in” orientation). In addition, the spacer length between two 
PAM sequences has limitations. Fourteen to 17 bp of spacer length exhibit higher on-target cleavage efficiency 
than other spacer lengths between 0 to 31 bp15. Based on these rules, this study chose the FokI-dCas9-sgRNA 
complex with a “PAM-out” orientation and spacer length of 17 bp. Moreover, it is worth noting that while a single 
FokI-dCas9-sgRNA can bind elsewhere in the genome, it cannot cleave DNA and cause off-target effects. In addi-
tion, FokI-dCas9 targets DNA sites with more than 140-fold higher specificity than normal SpCas9 and higher 
specificity than Cas9 nickases, which only cut single DNA strands throughout the genome23.
Although besides FokI-dCas9, strategies like Cas9 nickases or high-fidelity eSpCas9 variants24,25 can 
be adopted to enhance Cas9 specificity, we selected the FokI-dCas9 system to correct the PAH variant for its 
dual advantage of high specificity14 and potential improvement of HDR efficiency by DNA template pres-
ervation. It is generally known that the generation of HDR requires a large amount of DNA template. In the 
CRISPR/Cas9, eSpCas9 or Cas9 nickases systems, the DNA template can be cut by nucleases, even if an ssODN 
is used as the repair template. However, the FokI-dCas9-sgRNA complex cannot cleave the ssODN template 
as two distinct FokI-dCas9-sgRNA complexes have to bind to different DNA strands. Therefore, the CRISPR 
RNA-guided FokI nucleases system ensures a rich source of repair template during the HDR process. To further 
enhance HDR efficiency, a small-molecule drug was used in our study. The potent NHEJ inhibitor 5,6-bis((E)-
benzylideneamino)-2- mercaptopyrimidin-4-ol (SCR-7) and the HDR enhancer RS-1, can be used to improve 
nuclease-mediated HDR efficiency16,26. RS-1 shows greater potential than SCR-7 in improving the HDR rate 
in vivo17. Our study found that, after electroporation with the FokI-dCas9-sgRNA complex, the PAH_c.1222C>T 
COS-7 cells remaining in RS-1 culture medium showed more than twice as much PAH activity as negative con-
trols. Also, the PAH expression of the RS-1 group was significantly higher than cells grown without RS-1. The 
26.7% correction rate can be expected to provide a clinically sufficient therapeutic effect, as normal development 
has been reported in patients with PAH activities as low as 8.7–34.5% of normal27. RS-1 can increase knock-in 
efficiency by two- to five-fold in both the TALEN- and Cas9-mediated knock-in systems17. We found a similar 
improvement in HDR efficiency in the FokI-dCas9 system.
Using LC-ESI-MS-MS, we could determine in PAH_c.1222C>T COS-7 cells electroporated with the sgRNA 
plasmid, FokI-dCas9 plasmid and 1 nM ssODN and cultured in RS-1 a PAH activity of 22.1% compared to 8.8% in 
the control group. The goal of this study was not only the genetic repair of the PAH variant, but also the rescue of 
PAH activity after correction. The rescue of PAH activity demonstrates that our strategy is a promising approach 
for PKU treatment.
In conclusion, this study indicates that the FokI-dCas9 system is a suitable, specific and effective genome edit-
ing technique for correcting a major PAH variant that causes PKU. This highlights its tremendous potential for 
the precise treatment of also other inherited metabolic diseases.
Methods
Construction of the PAH_c.1222C>T vector and establishment of the PAH_c.1222C>T COS-7 
cell line. A wild-type PAH cDNA was cloned into the pLVX-EF1α -IRES-Puro vector (Clontech) using Xbal 
and BamHI cleavage (Thermo Fisher Scientific) after the amplification of cDNA from the pCMV-FLAG-PAH 
wild-type plasmid. The PAH_c.1222C>T variant in the PAH cDNA sequence was introduced by site-directed 
mutagenesis using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) and confirmed by 
Sanger DNA sequencing (GATC Biotech). EF1α forward and IRES reverse sequencing primers (Thermo Fisher 
Scientific) were used to sequence the PAH_c.1222C>T variant.
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COS-7 cells were cultured at 37 °C with 5% CO2 in Dulbecco’s Modified Eagle Medium (Thermo Fisher 
Scientific) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. One day prior to trans-
fection, 2 × 106 cells were seeded and cultured in one dish of 10 cm diameter. The transfection of one dish utilized 
45 μ L Fugene HD reagent (Promega) and 15 μ g PAH_c.1222C>T plasmid or the plasmid with the wild-type 
sequence as a control. Forty-eight hours post transfection, the growth medium was replaced with complete 
growth medium containing 10 μ g/mL puromycin as the selective agent. After the non-transfected COS-7 cells had 
died, a single PAH_c.1222C>T COS-7 clone was isolated using limiting dilution cloning technique performed in 
96-well plates with 10 μ g/mL puromycin remaining in the culture medium. The clone was characterized through 
RT-PCR, and expanded in 75 cm2 cell culture flasks.
Construction of the CRISPR RNA-guided FokI system plasmids and the HDR donor. The 
IRES-ZsGreen1 fragment of the pLVX-EF1α -IRES-ZsGreen1 vector (Clontech, Mountain View, USA), was 
used to construct by means of the Megaprimer PCR method28 the FokI-dCas9-IRES-ZsGreen1 plasmid 
(Supplementary Fig. 1b).
gRNAs, targeting the PAH_c.1222C>T variant were designed with the E-CRISP software tool (www.e-crisp.org)29. 
One suitable gRNA pair, which is composed of two separate gRNAs, was chosen as previously described15. gRNA 
pairs should be located on either side of the target in the PAM-out orientation and contain spacer of 14–17 bp in 
length. The final sgRNA expression fragment (Supplementary Table 2) was synthesized using gBlocks (Integrated 
DNA Technologies). It contains two separate U6 promoters, gRNAs and tracrRNAs, but is free of any 5′ modi-
fications. The synthesized sgRNA fragment was cloned into the pRSI9 vector (Cellecta) using Gibson Assembly 
Cloning (New England Biolabs) resulting in the pRSI9-1222sgRNA plasmid (Supplementary Fig. 1c).
The ssODN was synthesized using an HDR template from Integrated DNA Technologies. The homology arm 
of the HDR template located on the 5′ end of the PAH_c.1222C>T variant position is 71 nt and the arm on the 3′ 
end is 111nt (Supplementary Table 2).
Electroporation of PAH_c.1222C>T COS-7 cells. Electroporation was performed according to the 
instructions provided with the Gene Pulse Xcell electroporation system (Bio-Rad). Prior to electroporation, 
PAH_c.1222C>T COS-7 cells were washed with PBS and resuspended in Gene Pulser electroporation buffer 
(Bio-Rad) at 2.5 × 106 cells/mL. Ten micrograms of pRSI9-1222sgRNA plasmid, 10 μ g FokI-dCas9-zsGreen plas-
mid and 0.1 nM to 1 nM ssODN were added to the 0.4 cm cuvette with 400 μ L cells and mixed gently. The opti-
mized electroporation setting for PAH_c.1222C>T COS-7 cells was previously determined to be the following: 
pulse type (square wave), V (200 V), PL (15 msec) and cuvette (0.4 cm). After electroporation, 400 μ L of the elec-
troporated cells were transferred into 6-well plates. These electroporated cells were cultured in complete growth 
medium with or without 15 μ M RS-1 (Sigma-Aldrich) at 37 °C for 96 hours.
Flow cytometry analysis. Ninety-six hours after electroporation, cell pellets were harvested by centrifuga-
tion at 200 g for 4 min and resuspended in PBS buffer to 0.5 × 106 cells/mL. Flow cytometry analysis was performed 
on a BD FACSVerse™ flow cytometer (BD Biosciences). PAH_c.1222C>T COS-7 cells containing the 1222sgRNA 
plasmid were identified as PE positive while cells transfected with the FokI-dCas9-zsGreen plasmid were FITC 
positive. When the 1222sgRNA and FokI-dCas9-zsGreen plasmids were co-expressed, the cell group was gated 
as both PE and FITC positive group. The data were acquired and analyzed with FLOWJO software (FLOWJO).
Measurement of PAH activity by liquid chromatography-electrospray ionization tandem mass 
spectrometry. The PAH activity of the cell lysates was measured using previously described methods30. In 
brief, 5 μ L (containing 5–10 μ g of total protein) of cell homogenate obtained from PAH_c.1222C>T COS-7 cells 
after electroporation was mixed with 0.1 M Na-HEPES buffer, 2 μ g catalase and 1 M L-Phe and incubated for 5 min. 
One μ M Fe(NH4)2(SO4)2 was added into the mixture for one minute. PAH assay reaction was started by adding 
200 μ M BH4 and then incubated at 25 °C for 15 min. The reaction was stopped by adding 50 μ L of 2% (w/v) ace-
tic acid in ethanol. Then, the PAH samples were prepared for liquid chromatography-electrospray ionization tan-
dem mass spectrometry in accordance with the EZ:faastTM kit manual (Phenomenex). Ten microliters of 100 μ M 
Phe-d5 and 10 μ L of 20 μ M Tyr-d4 were added to 80 μ L PAH assay samples. The Phe and Tyr concentrations were calcu-
lated from an internal standard ratio. The specific PAH activity was expressed as mU/mg total protein, with mU equal 
to nmol Tyr produced. The PAH activity of PAH_wild-type COS-7 cells was used as a positive control and set at 100%.
Immunoquantification by Western blot analysis. Small amounts (10–15 μ g) of protein lysate from the 
PAH activity assay were used to detect PAH expression by Western blot. An anti-PAH antibody (Merck Millipore) 
and an anti-β -actin antibody (Santa Cruz Biotechnology) were used as primary antibodies at a 1:5,000 dilution 
and 1:2,000 dilution, respectively. A goat anti-mouse IgG-HRP conjugated to horseradish peroxidase (Santa Cruz 
Biotechnology) was used as the secondary antibody for detection at a 1:10,000 dilution. Signals were gener-
ated and recorded using the SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) as 
described by the manufacturer’s instructions.
TA cloning and sequencing of the PAH_c.1222C>T variant reversal. Genomic DNA from elec-
troporated PAH_c.1222C> T COS-7 cells was extracted using NucleoSpin Tissue (Macherey-Nagel) accord-
ing to the manufacturer’s instructions. PCR amplification of the mutated target sites was performed with Q5 
High-Fidelity DNA Polymerase (New England Biolabs) at standard conditions. The PCR product was purified 
with the PureLink PCR Purification Kit (Thermo Fisher Scientific). Poly-A tailing of the purified DNA was com-
pleted using Taq Polymerase (Qiagen), followed by cloning into plasmid pMD19-T (Clontech). Upon transfor-
mation into E. coli cells and colony growth, DNA was isolated from individual colonies and analyzed by Sanger 
sequencing, using EF1α forward and IRES reverse sequencing primers.
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Sanger sequencing for off-target analysis. The potential off-target sites have been predicted using 
CasOT (http://eendb.zfgenetics.org/casot/)31, a genome-wide potential Cas9-gRNA off-target searching online 
tool. The genomic region surrounding the candidate off-target sites were PCR-amplified with Q5 High-Fidelity 
DNA Polymerase (New England Biolabs) at standard conditions, and the PCR products were purified using 
PureLink PCR Purification Kit (Thermo Fisher Scientific). Sanger sequencing was utilized to detect their 
sequences using primers which covered the regions of these sites.
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